204 related articles for article (PubMed ID: 35064560)
1. Tryptophan 2,3-Dioxygenase-2 in Uterine Leiomyoma: Dysregulation by MED12 Mutation Status.
Hutchinson AP; Yin P; Neale I; Coon JS; Kujawa SA; Liu S; Bulun SE
Reprod Sci; 2022 Mar; 29(3):743-749. PubMed ID: 35064560
[TBL] [Abstract][Full Text] [Related]
2. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan catabolism is dysregulated in leiomyomas.
Chuang TD; Quintanilla D; Boos D; Khorram O
Fertil Steril; 2021 Oct; 116(4):1160-1171. PubMed ID: 34116832
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
5. Further characterization of tryptophan metabolism and its dysregulation in fibroids.
Chuang TD; Quintanilla D; Boos D; Khorram O
F S Sci; 2022 Nov; 3(4):392-400. PubMed ID: 35715314
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma.
Liu S; Yin P; Kujawa SA; Coon JS; Okeigwe I; Bulun SE
Oncogene; 2019 Apr; 38(15):2722-2735. PubMed ID: 30538295
[TBL] [Abstract][Full Text] [Related]
7. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
8. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
9. Introduction of Somatic Mutation in MED12 Induces Wnt4/β-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell.
El Andaloussi A; Al-Hendy A; Ismail N; Boyer TG; Halder SK
Reprod Sci; 2020 Mar; 27(3):823-832. PubMed ID: 32046450
[TBL] [Abstract][Full Text] [Related]
10. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
11. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
12. A mediator complex subunit 12 gain-of-function mutation induces partial leiomyoma cell properties in human uterine smooth muscle cells.
Takao T; Ono M; Yoshimasa Y; Masuda H; Maruyama T
F S Sci; 2022 Aug; 3(3):288-298. PubMed ID: 35643626
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of the mediator kinase-dependent myometrial stem cell phosphoproteome.
Barron L; Khadka S; Schenken R; He L; Blenis J; Blagg J; Chen SF; Tsai KL; Boyer TG
F S Sci; 2021 Nov; 2(4):383-395. PubMed ID: 35559861
[TBL] [Abstract][Full Text] [Related]
14. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
15. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
16. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
[TBL] [Abstract][Full Text] [Related]
17. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
19. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
20. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
